Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €5.51 EUR
Change Today -0.04 / -0.72%
Volume 7.6K
As of 11:29 AM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

biohit oyj-b (BIOBV) Snapshot

Open
€5.56
Previous Close
€5.55
Day High
€5.59
Day Low
€5.51
52 Week High
05/6/14 - €7.86
52 Week Low
12/30/14 - €4.57
Market Cap
76.0M
Average Volume 10 Days
14.1K
EPS TTM
€-0.31
Shares Outstanding
11.2M
EX-Date
04/15/15
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOHIT OYJ-B (BIOBV)

Related News

No related news articles were found.

biohit oyj-b (BIOBV) Related Businessweek News

No Related Businessweek News Found

biohit oyj-b (BIOBV) Details

Biohit Oyj, a biotechnology company, manufactures diagnostics products and diagnostics analysis systems for use in research institutions, and healthcare and industrial laboratories worldwide. Its diagnostic tests product range includes the blood-sample based GastroPanel test for diagnosing diseases of the stomach and associated risks; quick tests for the diagnosis of lactose intolerance, Helicobacter pylori infection, and Celiac disease; and ColonView for the early detection of fecal occult blood. The company’s diagnostic tests are also used for the identification of patients at increased risk of gastric cancer, peptic ulcer disease, and gastroesophageal reflux disease, as well as deficiencies of vitamin B12, calcium, and iron. In addition, it provides acetaldehyde binding products, Acetium capsules intended for persons with a low-acid or anacidic stomach; and Acetium lozenges for removing acetaldehyde in smoker's saliva. Further, the company produces monoclonal antibodies for human gastric biomarkers, phytoestrogen genistein, human extracellular matrix components, human integrins, human endothelial cell surface markers, human neurotransmitter substances, human cytoskeletal polypeptides, human spectrins, and phytoestrogen. Additionally, the company provides microplate readers and strip washers for diagnostics, research, and clinical laboratory instrumentation; and mechanical and electronic pipettes, and disposable pipette tips, as well as analyses carcinogenic acetaldehyde in foodstuff, and non-alcoholic and alcoholic beverages. The company was founded in 1988 and is headquartered in Helsinki, Finland.

51 Employees
Last Reported Date: 03/30/15
Founded in 1988

biohit oyj-b (BIOBV) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

biohit oyj-b (BIOBV) Key Developments

Biohit Oyj Proposes Amendments to the Articles of Association

Biohit Oyj announced that at its annual general meeting to be held on April 20, 2015, the shareholders has proposed the amendments to the Articles of Association.

Biohit Oyj Signs Distribution Agreement with Oriola Oy for the Distribution of Acetium Capsules and Acetium Lozenges in Finland

Biohit Oyj signed a distribution agreement with Oriola Oy. The agreement is effective after a transition period (first half of 2015) and will replace the previous distribution agreement in Finland. With the agreement, Oriola gains exclusive rights for the distribution of Acetium® capsules and Acetium® lozenges in Finland. Acetium® capsules efficiently bind (neutralize) carcinogenic acetaldehyde in an achlorhydric stomach. This contributes to the prevention of cancer in the mouth, stomach and oesophagus.  Acetium® capsules are intended e.g. for PPI users and persons suffering from an achlorhydric stomach caused by atrophy of the gastric mucosa and functional disorder (atrophic gastritis).  Atrophic gastritis can be found by a blood sample based on GastroPanel® test and can be caused by Helicobacter pylori infection, or as a result of an autoimmune disease. An anacidic stomach is the most significant risk factor for stomach and oesophageal cancer. The Acetium® lozenge is intended to protect the mouth by binding acetaldehyde dissolved into saliva during smoking and alcohol consumption. Acetaldehyde is the most important carcinogen in cigarette smoke.

Biohit Oyj Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Sales Guidance for the Year 2015

Biohit Oyj announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, net sales were EUR 1.1 million against EUR 0.8 million a year ago. Operating loss from continuing operations was EUR 1.2 million against EUR 1.5 million a year ago. Loss before taxes was EUR 1.2 million against EUR 1.6 million a year ago. Loss for the period from continuing operations was EUR 1.2 million against EUR 1.6 million a year ago. Total loss for the period was EUR 1.2 million against EUR 1.6 million a year ago. For the year, net sales were EUR 4.4 million against EUR 3.5 million a year ago. Operating loss from continuing operations was EUR 4.5 million against EUR 5.9 million a year ago. Loss before taxes was EUR 4.3 million against EUR 5.9 million a year ago. Loss for the period from continuing operations was EUR 4.4 million against EUR 5.9 million a year ago. Total loss for the period was EUR 1.2 million against EUR 5.9 million a year ago. Undiluted loss per share from continuing operations was EUR 0.32 against EUR 0.43 a year ago. Net cash outflow from operating activities was EUR 3.4 million against EUR 4.4 million a year ago. Investments in tangible and intangible assets was EUR 0.4 million against EUR 0.5 million a year ago. The company aim to grow profitable and are strongly committed to taking necessary actions in order to build a profitable future for the company and net sales growth is expected in 2015. The company does not assess when the result of its continuing operations will turn to positive.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOBV:FH €5.51 EUR -0.04

BIOBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BIOBV.
View Industry Companies
 

Industry Analysis

BIOBV

Industry Average

Valuation BIOBV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.0x
Price/Book 5.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOHIT OYJ-B, please visit www.biohithealthcare.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.